CN1376461A - 基于硫辛酸和聚烯醇脂肪酸的活性组分 - Google Patents
基于硫辛酸和聚烯醇脂肪酸的活性组分 Download PDFInfo
- Publication number
- CN1376461A CN1376461A CN02107839A CN02107839A CN1376461A CN 1376461 A CN1376461 A CN 1376461A CN 02107839 A CN02107839 A CN 02107839A CN 02107839 A CN02107839 A CN 02107839A CN 1376461 A CN1376461 A CN 1376461A
- Authority
- CN
- China
- Prior art keywords
- acid
- compositions
- weight
- active component
- alopecia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000019136 lipoic acid Nutrition 0.000 title claims abstract description 33
- 229960002663 thioctic acid Drugs 0.000 title claims abstract description 33
- 235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 14
- 239000000194 fatty acid Substances 0.000 title claims abstract description 14
- 229930195729 fatty acid Natural products 0.000 title claims abstract description 14
- 150000004665 fatty acids Chemical class 0.000 title claims abstract description 12
- 239000004480 active ingredient Substances 0.000 title abstract 3
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 title abstract 2
- 150000005846 sugar alcohols Polymers 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 57
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 8
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 8
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 8
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims abstract description 8
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 239000002537 cosmetic Substances 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract description 6
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims abstract description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 5
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims description 31
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 31
- 230000000694 effects Effects 0.000 claims description 19
- -1 oleic fatty acid Chemical class 0.000 claims description 13
- 201000004384 Alopecia Diseases 0.000 claims description 12
- 231100000360 alopecia Toxicity 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 8
- 230000000474 nursing effect Effects 0.000 claims description 8
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 8
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 5
- 206010043189 Telangiectasia Diseases 0.000 claims description 5
- 206010000496 acne Diseases 0.000 claims description 5
- 208000009056 telangiectasis Diseases 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- IJFXRHURBJZNAO-UHFFFAOYSA-N 3-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1 IJFXRHURBJZNAO-UHFFFAOYSA-N 0.000 claims description 4
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 claims description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
- 208000025865 Ulcer Diseases 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 201000011066 hemangioma Diseases 0.000 claims description 4
- 206010021198 ichthyosis Diseases 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000001968 nicotinic acid Nutrition 0.000 claims description 4
- 229960003512 nicotinic acid Drugs 0.000 claims description 4
- 239000011664 nicotinic acid Substances 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 229960004889 salicylic acid Drugs 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 231100000397 ulcer Toxicity 0.000 claims description 4
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 3
- 150000003254 radicals Chemical class 0.000 claims description 3
- 231100000241 scar Toxicity 0.000 claims description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 3
- 235000010384 tocopherol Nutrition 0.000 claims description 3
- 229960001295 tocopherol Drugs 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 3
- HEOCBCNFKCOKBX-RELGSGGGSA-N (1s,2e,4r)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical group C1=CC(C)=CC=C1\C=C/1C(=O)[C@]2(C)CC[C@H]\1C2(C)C HEOCBCNFKCOKBX-RELGSGGGSA-N 0.000 claims description 2
- OIQXFRANQVWXJF-QBFSEMIESA-N (2z)-2-benzylidene-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical group CC1(C)C2CCC1(C)C(=O)\C2=C/C1=CC=CC=C1 OIQXFRANQVWXJF-QBFSEMIESA-N 0.000 claims description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 2
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 claims description 2
- ORWUQAQITKSSRZ-UHFFFAOYSA-N 2-hydroxyethyl 4-[bis[2-(2-hydroxyethoxy)ethyl]amino]benzoate Chemical compound OCCOCCN(CCOCCO)C1=CC=C(C(=O)OCCO)C=C1 ORWUQAQITKSSRZ-UHFFFAOYSA-N 0.000 claims description 2
- KKJKXQYVUVWWJP-JLHYYAGUSA-N 4-[(e)-(4,7,7-trimethyl-3-oxo-2-bicyclo[2.2.1]heptanylidene)methyl]benzenesulfonic acid Chemical compound CC1(C)C2CCC1(C)C(=O)\C2=C\C1=CC=C(S(O)(=O)=O)C=C1 KKJKXQYVUVWWJP-JLHYYAGUSA-N 0.000 claims description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010012455 Dermatitis exfoliative Diseases 0.000 claims description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims description 2
- 206010014201 Eczema nummular Diseases 0.000 claims description 2
- 206010053717 Fibrous histiocytoma Diseases 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- 206010018691 Granuloma Diseases 0.000 claims description 2
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 2
- 208000001126 Keratosis Diseases 0.000 claims description 2
- 206010064000 Lichenoid keratosis Diseases 0.000 claims description 2
- 208000000185 Localized scleroderma Diseases 0.000 claims description 2
- 206010027982 Morphoea Diseases 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- 201000009053 Neurodermatitis Diseases 0.000 claims description 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 2
- 206010039796 Seborrhoeic keratosis Diseases 0.000 claims description 2
- 206010040865 Skin hyperpigmentation Diseases 0.000 claims description 2
- 206010041955 Stasis dermatitis Diseases 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 2
- 206010070863 Toxicity to various agents Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 206010048218 Xeroderma Diseases 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 229930002945 all-trans-retinaldehyde Natural products 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- UBNYRXMKIIGMKK-RMKNXTFCSA-N amiloxate Chemical compound COC1=CC=C(\C=C\C(=O)OCCC(C)C)C=C1 UBNYRXMKIIGMKK-RMKNXTFCSA-N 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000001119 benign fibrous histiocytoma Diseases 0.000 claims description 2
- 229960001716 benzalkonium Drugs 0.000 claims description 2
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 claims description 2
- 150000001277 beta hydroxy acids Chemical class 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 229940025250 camphora Drugs 0.000 claims description 2
- 239000010238 camphora Substances 0.000 claims description 2
- 230000004087 circulation Effects 0.000 claims description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 claims description 2
- 229960000655 ensulizole Drugs 0.000 claims description 2
- 229960004697 enzacamene Drugs 0.000 claims description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 2
- 229940068171 ethyl hexyl salicylate Drugs 0.000 claims description 2
- 208000004526 exfoliative dermatitis Diseases 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 229960004881 homosalate Drugs 0.000 claims description 2
- 210000000835 hypertrophic cicatrix Anatomy 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 201000011486 lichen planus Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- JZMJDSHXVKJFKW-UHFFFAOYSA-N methyl sulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 claims description 2
- 230000004089 microcirculation Effects 0.000 claims description 2
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 claims description 2
- 229960001679 octinoxate Drugs 0.000 claims description 2
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical compound C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 claims description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 claims description 2
- 229960001173 oxybenzone Drugs 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 2
- 235000020945 retinal Nutrition 0.000 claims description 2
- 239000011604 retinal Substances 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 claims description 2
- 235000020944 retinol Nutrition 0.000 claims description 2
- 229960003471 retinol Drugs 0.000 claims description 2
- 239000011607 retinol Substances 0.000 claims description 2
- 235000019192 riboflavin Nutrition 0.000 claims description 2
- 229960002477 riboflavin Drugs 0.000 claims description 2
- 239000002151 riboflavin Substances 0.000 claims description 2
- 235000005493 rutin Nutrition 0.000 claims description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 2
- 229960004555 rutoside Drugs 0.000 claims description 2
- 201000003385 seborrheic keratosis Diseases 0.000 claims description 2
- 239000008347 soybean phospholipid Substances 0.000 claims description 2
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000368 sulisobenzone Drugs 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 235000019157 thiamine Nutrition 0.000 claims description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003495 thiamine Drugs 0.000 claims description 2
- 239000011721 thiamine Substances 0.000 claims description 2
- 230000001228 trophic effect Effects 0.000 claims description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims description 2
- 208000035484 Cellulite Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 206010049752 Peau d'orange Diseases 0.000 claims 1
- 230000003579 anti-obesity Effects 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000036232 cellulite Effects 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 238000009499 grossing Methods 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 201000002282 venous insufficiency Diseases 0.000 claims 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 abstract description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 abstract description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 abstract description 4
- 239000005642 Oleic acid Substances 0.000 abstract description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 abstract description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 abstract description 4
- 235000021313 oleic acid Nutrition 0.000 abstract description 4
- 235000005911 diet Nutrition 0.000 abstract description 2
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 2
- 230000002503 metabolic effect Effects 0.000 abstract description 2
- 230000000378 dietary effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 35
- 210000003491 skin Anatomy 0.000 description 26
- 238000000034 method Methods 0.000 description 18
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 16
- 208000012641 Pigmentation disease Diseases 0.000 description 11
- 239000000499 gel Substances 0.000 description 10
- 230000019612 pigmentation Effects 0.000 description 10
- 239000002253 acid Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 6
- 238000002310 reflectometry Methods 0.000 description 6
- 230000003796 beauty Effects 0.000 description 5
- 238000004042 decolorization Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- ZQCIPRGNRQXXSK-UHFFFAOYSA-N 1-octadecoxypropan-2-ol Chemical compound CCCCCCCCCCCCCCCCCCOCC(C)O ZQCIPRGNRQXXSK-UHFFFAOYSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 239000005662 Paraffin oil Substances 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000007766 cera flava Substances 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 229940078491 ppg-15 stearyl ether Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940084106 spermaceti Drugs 0.000 description 3
- 239000012177 spermaceti Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000010902 straw Substances 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 2
- 229940031016 ethyl linoleate Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000036564 melanin content Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000013139 quantization Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241001072256 Boraginaceae Species 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 241001312569 Ribes nigrum Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 229920001492 Tholin Polymers 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003026 anti-oxygenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000007682 dermal toxicity Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- JYYFMIOPGOFNPK-AGRJPVHOSA-N ethyl linolenate Chemical compound CCOC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC JYYFMIOPGOFNPK-AGRJPVHOSA-N 0.000 description 1
- 229940090028 ethyl linolenate Drugs 0.000 description 1
- JYYFMIOPGOFNPK-UHFFFAOYSA-N ethyl linolenate Natural products CCOC(=O)CCCCCCCC=CCC=CCC=CCC JYYFMIOPGOFNPK-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000985 reflectance spectrum Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
- F01L—CYCLICALLY OPERATING VALVES FOR MACHINES OR ENGINES
- F01L1/00—Valve-gear or valve arrangements, e.g. lift-valve gear
- F01L1/02—Valve drive
- F01L1/04—Valve drive by means of cams, camshafts, cam discs, eccentrics or the like
- F01L1/047—Camshafts
- F01L1/053—Camshafts overhead type
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
- F01L—CYCLICALLY OPERATING VALVES FOR MACHINES OR ENGINES
- F01L9/00—Valve-gear or valve arrangements actuated non-mechanically
- F01L9/10—Valve-gear or valve arrangements actuated non-mechanically by fluid means, e.g. hydraulic
- F01L9/11—Valve-gear or valve arrangements actuated non-mechanically by fluid means, e.g. hydraulic in which the action of a cam is being transmitted to a valve by a liquid column
- F01L9/12—Valve-gear or valve arrangements actuated non-mechanically by fluid means, e.g. hydraulic in which the action of a cam is being transmitted to a valve by a liquid column with a liquid chamber between a piston actuated by a cam and a piston acting on a valve stem
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
- F01L—CYCLICALLY OPERATING VALVES FOR MACHINES OR ENGINES
- F01L1/00—Valve-gear or valve arrangements, e.g. lift-valve gear
- F01L1/34—Valve-gear or valve arrangements, e.g. lift-valve gear characterised by the provision of means for changing the timing of the valves without changing the duration of opening and without affecting the magnitude of the valve lift
- F01L1/344—Valve-gear or valve arrangements, e.g. lift-valve gear characterised by the provision of means for changing the timing of the valves without changing the duration of opening and without affecting the magnitude of the valve lift changing the angular relationship between crankshaft and camshaft, e.g. using helicoidal gear
- F01L1/3442—Valve-gear or valve arrangements, e.g. lift-valve gear characterised by the provision of means for changing the timing of the valves without changing the duration of opening and without affecting the magnitude of the valve lift changing the angular relationship between crankshaft and camshaft, e.g. using helicoidal gear using hydraulic chambers with variable volume to transmit the rotating force
- F01L2001/34423—Details relating to the hydraulic feeding circuit
- F01L2001/34446—Fluid accumulators for the feeding circuit
Landscapes
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- General Engineering & Computer Science (AREA)
- Valve Device For Special Equipments (AREA)
- Valve-Gear Or Valve Arrangements (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种活性组分,其中含有活性成分如硫辛酸,和至少一种脂肪酸,其选自亚油酸、亚麻酸、油酸,并且当将其配制入药用、食用和美容用组合物时,其适用于预防和治疗某些疾病,如皮肤、心血管的和代谢水平的疾病。
Description
所属领域
本发明涉及基于作为活性组分的硫辛酸和聚烯醇脂肪酸的新产品,其中制剂中的该活性组分用于不同皮肤瑕疵和皮肤病的药用治疗和美容护理。
在以下说明书中,该产品也被称为THIOLIN,并且聚烯醇脂肪酸也被称为AGE。
背景技术
硫辛酸是天然存在于人体中的辅酶,并能迅速转化成以二氢硫辛酸为代表的还原形式。
硫辛酸在克雷布氏三羧酸循环生化反应中充当辅酶;更具体说,在丙酮酸盐和某些酮酸的脱羧反应中充当辅酶。
硫辛酸也可用于治疗糖尿病,特别是糖尿病性神经病,其特征在于:通过其在亲水和亲油条件下的显著抗氧活性保护脂蛋白、膜、蛋白质结构和DNA,使其免受氧化造成的损伤。
硫辛酸可修复其他抗氧剂,如抗坏血酸和生育酚,增进谷胱甘肽的细胞内水平。AGE(亚油酸、亚麻酸和油酸)属于脂类,其为含有双键的羧酸,因此,它们也被称为多不饱和脂肪酸。AGE中的亚油酸和亚麻酸不能在有机体内合成,而必须从食物中摄取。AGE是存在于液体植物油中的一类物质的集合,其是形成细胞膜所必须的,而它们的缺乏会令离子不能通过细胞膜传输,其能维持细胞膜内的液体,保持动脉壁的弹性,其是甲状腺、肾上腺、粘膜、神经正常功能所必须的,其能滋养皮肤,使皮肤柔软和肤色调和,维持血流,并能调整免疫系统活性。
它们适用于预防心脏病,维持胆甾醇水平不变,预防血压升高,预防支气管性哮喘和类风湿性关节炎。它们存在于菜籽(琉璃苣、向日葵、玉米、橄榄、黑醋栗、藏红花)油中。有机体内缺乏AGE会造成前列腺素产生降低,特别是存在于前列腺、脑、肾、精液和月经中的脂肪酸产生降低。当食物中亚油酸的含量充足时,另外两种必要脂肪酸可由其合成得到。不饱和脂肪酸需求量的增加与所摄取的饱和脂肪酸的含量成正比。基于碳水化合物的饮食也会增加对不饱和脂肪酸的需求量。
发明目的和概述
经过申请人的大量研究,发现将硫辛酸和AGE以一种新产品形式联合应用时,其生物学、生理学和药理学活性会增加。
本发明是在对一系列复杂研究进行评估的基础上作出的。
本发明的目的实际上是提供一种新的活性组分,其具有改善的生物学、生理学、生化和药理学功能,其适用于制备外用和内服的药用、食用和美容用产品。
本发明的另一目的是提供适用于预防和治疗某些疾病的药用、食用和美容用产品组合物,这些疾病非限定性地通常为皮肤、心血管和代谢系统疾病。
可通过采用由硫辛酸和聚烯醇脂肪酸混合物构成的活性组分达到这些目的,其中硫辛酸的含量为0.5-90%(重量),优选5-50%(重量),并且其中由至少一种选自亚油酸、亚麻酸和油酸的脂肪酸与溶剂、增溶剂和稀释剂构成或仅由该至少一种脂肪酸构成剩余的百分比。
在说明书中,硫辛酸包括其还原成二氢硫辛酸的形式、右旋和左旋形式、外消旋混合物和相应的盐、酯和酰胺。
AGE包括上述的酸、其相应的盐、酯和酰胺,左旋和右旋形式,可为化学纯品形式和存在于提取物、动物油和植物油中。
对于用途和剂型,THIOLIN可配制成适用于美容、药用和食用的外用和内服组合物,其中含有适用于片剂、胶囊、注射用溶液、经皮膏剂、乳剂、软膏剂、糊剂、洗剂、溶液、油浸剂等剂型中的赋形剂、增效剂和其他适用的辅剂。组合物中的活性组分的用量为0.1-90%(重量),优选3-50%(重量)。在活性组分和含有活性组分的组合物中,硫辛酸在防止自由基在碳水化合物、蛋白质、核苷和脂类结构中造成的氧化损伤方面具有特殊和直接的作用,并且其可抑制AGE的过氧化和降解。
一般说来,将硫辛酸和AGE共用于美容、食用和药用组合物中的作用可通过以下事实证明:不同活性成分的联合作用是强活性的依据,该强活性能增加和强化各化合物单独应用时的药理学、生物学和生理学作用。
基于发明人的评估,THIOLIN对某些疾病的直接作用是可接受的和具有创新性的。作为对THIOLIN功效的证明,下文中报道了涉及THIOLIN脱色作用实验的结果。由所进行的不同实验的对比可知,THIOLIN可提高通过仅采用不同组分的混合物(硫辛酸或AGE)达到的脱色功效。
实验评估
近来,对测定皮肤内黑色素含量应用的非损伤性方法的某些研究引起了相当大的关注。为此所提出的不同技术中,色度计法和反射比分光光度计法是最受关注的。皮肤反射比色度计法中,采用可信的简单关联法测出皮肤内的色素沉积,该简单关联是CIE实验室系统的一个或多个色度计参数(L,a,b)与皮肤中黑色素含量之间的关联。另一方面,反射比分光光度计法是基于反射光谱测定出与皮肤中存在的发色基团直接和明确相关的黑色素指标(IM)。实际上黑色素的反射比光谱的特征在于:在UV区域的强吸收性,而在450nm-700nm的可见光区域中吸收性持续降低。此外,血红蛋白(皮肤中另一重要的发色基团)在650nm-700nm的光谱区域中没有吸收峰,而黑色素仍具有显著的吸收性。因此,基于这些证据,并基于皮肤在650nm-700nm区域内的反射比特性,Dawson(8)基于下式提出了黑色素参数(IM)的概念:
IM=LIR650-LIR700+0.015
其中LIR是采用反射比分光光度计分别在650和700测出的反射比倒数的对数,而0.015是根据装置而定的校正因子。IM值是650-700间形成直线的斜率,并且其可通过非损伤性的和快速的测定获得对皮肤中黑色素的光谱半定量测定值,同时不会受皮肤中存在的血红蛋白发色基团的影响。
该研究的目的是评估:与仅含硫辛酸或AGE中任一种的制剂相比,含THOLIN制剂的脱色作用,其中由经受了表皮色素沉积过程12名志愿者参加,色素沉积过程是通过紫外线照射进行的(采用日光模拟器-日光灯-Helios-Italquarz spa-Mila,Italy-UVA 1095mWat cm2,UVB1525mWat cm2-距离25cm-分别经低于红斑最低剂量(MED)的紫外线剂量照射)。为获得对黑色素生成过程的无偏差和可信的检测,采用非损伤性技术进行评估,如采用上述文献(2-8)中所述的反射比分光光度计法。
此外,为进行对照评估,测定含2%氢醌(HQ 2%)凝胶的脱色能力,其在化妆品领域中被广泛用于皮肤增白制剂中。测定脱色效果的方案
选用12名健康志愿者(属于光照II型和III型)测定脱色效果。在每人前臂的中心区域标记6处皮肤部位(1cm2)。首先测定这些部位的红斑指数值(IM基准值),然后采用可模拟日光的适用的灯经一周的受控照射方案照射这些部位。对于每一被测者,根据规定的照射时间使皮肤与日光接触,从而造成可观的皮肤色素沉着作用而不会导致红斑反应,该作用是可见的和仪器可测的。
以下是用于受控晒黑过程的日光照射方案:
第1天和第二天:2-4分钟照射(根据被测者实际情况而定)
第三天:停顿
第四天和第五天:4-6分钟照射(根据被测者实际情况而定)
第六天:停顿
第七天和第八天:6-8分钟照射(根据被测者实际情况而定)。
停顿日需要防止会改变黑色素指数测定的红斑反应(和可能的脱皮现象)。
每次经日晒后,迅速在每一被测者的四处被测皮肤部位上涂敷100mg的基于THIOLIN的制剂(涂于两处)、或硫辛酸(涂于另外两处)、或AGE(涂于另外两处)、或HQ2%制剂(涂于另外两处),另外两处被测部位被用于验证,因此不经处理(验证对照组)。
第一个八天(照射期)过后,被测者继续每日一次在照射皮肤部位上涂敷100mg各制剂(基于THIOLIN的制剂、硫辛酸、AGE和HQ2%制剂),持续涂敷3周以上。通过与初始基准值相比、测定各部位不同时间的黑色素指数的变化值(ΔIM)来进行对黑色素产生过程的监测。此外,为量化表示该脱色作用,计算ΔIM-时间曲线(AUC)对向的面积(areas subtended)数值;从而可由下式获得对黑色素产生过程的抑制百分比数值(PIP-色素沉着抑制百分比):
其中AUCc是对于验证对照部位(经日光灯照射但未经处理),其在AIM-时间曲线(AUC)对向的面积数值(监测期:约4周),而AUCt是对于经日光灯照射然后经被测制剂处理的部位,其在AIM-时间曲线(AUC)对向的面积数值。结果:
被测制剂(基于THIOLIN的制剂、硫辛酸、AGE和HQ2%制剂)可有效抑制健康志愿者经紫外线照射导致的色素沉着过程。
在典型的过程中,对某一被测者可观察到其红斑指数的变化,其为相对于时间的函数。
与未经处理的皮肤部位(验证对照组)相比,经基于THIOLIN的制剂处理、或仅用硫辛酸处理、或仅用AGE处理、或仅用HQ2%凝胶处理的皮肤部位的色素沉着密度和持久性低。
下表1所示的是由不同被测者得到的ΔIM-时间曲线上面积值(AUC),以及平均AUC值,如前所述,其与色素沉着密度和持续时间成正比。由表1中的数值可知,相应于经HQ2%凝胶处理的AUC与经基于THIOLIN制剂处理得到的数值相比并无明显差异(p>0.05),由此表明基于THIOLIN的制剂抑制黑色素产生观察的功效与HQ2%凝胶功效类似,并且高于仅基于硫辛酸或AGE的制剂的功效。通过计算色素沉着抑制百分比值(PIP)来量化表示被测制剂的脱色作用时,得出的HQ2%凝胶和基于THIOLIN的制剂的PIP值分别是68.1和63.4,而仅含硫辛酸或AGE的制剂的值分别是51.7和53.7(表2)。
这些试验所得的结果说明基于THIOLIN的制剂对于皮肤色素沉着过程可产生明显的抑制作用。该脱色作用与采用HQ2%凝胶(广泛用于脱色美容产品中的成分,但其具有较大皮肤毒性)的效果相比并无明显差异,同时其作用高于仅含硫辛酸或AGE的制剂的作用。
根据所得结果,具有THIOLIN的制剂可作为氢醌(有效的脱色物质,但具有高毒性特征)的有效替代用品,并且其作用显然高于单独采用硫辛酸或AGE作为脱色剂时的作用。
表1-在色素沉着过程中,对于某一被测者,分别经THIOLIN、硫辛酸、AGE和HQ2%凝胶处理或未经处理(验证对照组)得到的ΔIM-时间曲线上相应面积的值。
验证对照组 | THIOLIN | 硫辛酸 | AGE | HQ2% | |
平均值 | 1250.6 | 456.8 | 641.7 | 532.3 | 399.1 |
D.S. | 194.3 | 78.6 | 145.8 | 113.3 | 73.9 |
P.I.P | ---- | 63.4 | 51.7 | 53.7 | 68.1 |
表2-分别由THIOLIN、硫辛酸、AGE和HQ2%凝胶得到的黑色素产生过程抑制百分比数值(PIP)THIOLIN制剂的实例
可采用以下方法制备THIOLIN:
制剂A1
说明 | %(重量) | |
01 | 硫辛酸 | 40 |
02 | 亚油酸 | 40 |
03 | ethylic acid | 20 |
如何制备:在03中稀释01+02
制剂A2
说明 | %(重量) | |
01 | 硫辛酸 | 40 |
02 | 亚麻酸 | 40 |
03 | ethylic acid | 20 |
如何制备:在03中稀释01+02
制剂A3
说明 | %(重量) | |
01 | 硫辛酸 | 40 |
02 | 油酸 | 40 |
03 | ethylic acid | 20 |
如何制备:在03中稀释01+02
制剂A4
说明 | %(重量) | |
01 | 硫辛酸 | 20 |
02 | 油酸 | 40 |
03 | 亚麻酸 | 20 |
04 | 亚油酸 | 20 |
如何制备:混合02+03+04,并在混合物中稀释01
制剂A5
说明 | %(重量) | |
01 | 硫辛酸 | 40 |
02 | 亚油酸乙酯 | 60 |
如何制备:在02中稀释01
制剂A6
说明 | %(重量) | |
01 | 硫辛酸 | 20 |
02 | 亚油酸乙酯 | 60 |
03 | 油酸乙酯 | 10 |
04 | 亚麻酸乙酯 | 10 |
如何制备:混合02+03+04,并在混合物中稀释01
为获得对化学、物理、化学-物理、生物、生理、药理和美容作用的进一步和显著的改善,可将THIOLIN与其他化学成分(增效剂)共用,其可分别依次施用或共用。
可将增效剂直接加入含THIOLIN化合物的制剂中,或以其他药用或美容用制剂的形式应用,该其他制剂可以是内服形式的(片剂、胶囊、糖浆、注射剂等剂型),或是可外用于皮肤和/或粘膜的形式(乳剂、单相溶液、两相溶液、散剂等)。
以下化学成分可用作增效剂:视黄醇、视黄醛、生育酚、抗坏血酸、生物素、对氨基苯甲酸、芦丁胡、β-萝卜素、硫胺素、核黄素、吡哆辛、吡哆醛、烟碱酸、烟酸、烟酰胺、泛酸、泛醇、叶酸、卵磷脂、大豆磷脂例如磷脂酰胆碱、磷脂酰乙醇胺、磷脂酸、溶血磷脂酰胆碱、PABA胡莫柳酯、樟脑甲硫酸苯甲烃铵、二苯酮-3、苯基苯并咪唑磺酸、丁基甲氧基苯甲酰甲烷、对苯二亚甲基二樟脑磺酸、亚苄基樟脑磺酸、氯双苯丙烯酸辛酯、甲氧基肉桂酸辛酯、聚丙烯酰氨基甲基亚苄基、PEG-25 PABA、水杨酸辛酯、二甲基PABA辛酯、对甲氧基肉桂酸异戊酯、二苯酮-4、3-亚苄基樟脑、4-甲基亚苄基樟脑、水杨酸异丙基苄酯、辛基-triazonesia、α-羟基酸和β-羟基酸,单羧酸和二羧酸,例如乙醇酸、乳酸(右旋和左旋形式,以及消旋混合物形式)、酒石酸(右旋和左旋形式,以及消旋混合物形式)、苹果酸(右旋和左旋形式,以及消旋混合物形式)、水杨酸、3-羟基苯甲酸、4-羟基苯甲酸、柠檬酸,这些成分可单用或共用,包括其相应的盐、酯和酰胺,以及相应的D-L-DL形式,以上组分可以百分比0.001-50%(重量)、优选0.05-15%(重量)与THIOLIN共用。
将THIOLIN任选地与增效共用在美容应用方面也是创新性的,如:可采用具有防老化作用的活性成分,它们旨在改善皮肤美观性和防止皮肤老化现象、抗皱、滋润、用于调理皮肤过度色素沉着、雀斑、其他黑色素沉积现象、sideremia导致的皮肤色斑、皮脂溢的美容护理、易于产生痤疮的皮脂溢皮肤的美容护理、秃发的美容护理、蜂窝组织炎的美容护理;并且可将THIOLIN任选地与增效共用于药用领域,以防止和治疗某些病理性症状,如:特应性(athopic)皮炎、脂溢性皮炎、钱币状皮炎、剥脱性皮炎、停滞性皮炎、神经性皮炎、痤疮、红斑痤疮、瘢痕性脱发、希波克拉底氏脱发、女性脱发(femalealopecia)、药物毒性脱发、aerate脱发、假性毛囊炎、牛皮癣、扁平红苔癣、鱼鳞癣、干皮病、角化病、褥疮、营养不良性溃疡、钝痛、血管瘤、haemangioma、毛细管扩张肉芽瘤、脂溢性角化病、纤维组织细胞瘤、硬斑病,治疗肥大性瘢痕、烧伤瘢痕、毛细管扩张,改善循环和微循环、瘀血、血管淤滞(vascular stagnation)、红斑狼疮、伤口瘢痕、因氧化作用导致的疾病、动脉压过高等。
THIOLIN化合物可任选地与上述适用的增效剂共用于外用制剂如油包水型乳剂、水包油型乳剂、单相溶液、两相假性溶液、单相凝胶、两相凝胶、无水软膏、散剂等中,其中采用适用的载体或赋形剂,或用于内服制剂如片剂、胶囊、糖浆、注射剂、栓剂中。
采用以下制剂实施例进一步说明本发明的组合物。
除非特别指出,其中的比例均以占成品的重量百分比计。制剂实施例1:
淡化色斑用产品
如何制备:
成分 | 重量百分比 |
硬脂基醚-21 | 2.000 |
硬脂酸甘油酯 | 3.000 |
环甲基聚硅氧烷 | 1.000 |
PPG-15-硬脂基醚 | 2.000 |
蜂蜡 | 2.000 |
硬脂酸 | 1.500 |
葵花籽油 | 6.000 |
鲸蜡酸 | 1.000 |
石蜡油 | 4.000 |
麦草油 | 1.000 |
THIOLIN | 7.500 |
成分(B) | 重量百分比 |
防腐剂 | 适量 |
香精 | 适量 |
水 | 适量 |
将成分(A)和(B)分别加热至70℃。然后将成分(B)加入成分(A)中,共同混合得到适于局部应用的乳化体形式的均质混合物。制剂实施例2:
淡化色斑用产品组分THIOLIN 7.500增溶剂 适量水 适量如何制备:采用增溶剂将THIOLIN溶于水中。制剂实施例4:
抗痤疮产品
如何制备:
成分 | 重量百分比 |
硬脂基醚-21 | 2.000 |
硬脂酸甘油酯 | 3.000 |
环甲基聚硅氧烷 | 1.000 |
PPG-15-硬脂基醚 | 2.000 |
蜂蜡 | 2.000 |
硬脂酸 | 1.500 |
葵花籽油 | 6.000 |
鲸蜡酸 | 1.000 |
石蜡油 | 4.000 |
麦草油 | 1.000 |
THIOLIN | 7.500 |
成分(B) | 重量百分比 |
防腐剂 | 适量 |
香精 | 适量 |
水 | 适量 |
将成分(A)和(B)分别加热至70℃。然后将成分(B)加入成分(A)中,共同混合得到适于局部应用的乳化体形式的均质混合物。制剂实施例4:
特应性皮炎用产品
如何制备:
成分 | 重量百分比 |
硬脂基醚-21 | 2.000 |
硬脂酸甘油酯 | 3.000 |
环甲基聚硅氧烷 | 1.000 |
PPG-15-硬脂基醚 | 2.000 |
蜂蜡 | 2.000 |
硬脂酸 | 1.500 |
葵花籽油 | 6.000 |
鲸蜡酸 | 1.000 |
石蜡油 | 4.000 |
麦草油 | 1.000 |
THIOLIN | 7.500 |
成分(B) | 重量百分比 |
防腐剂 | 适量 |
香精 | 适量 |
水 | 适量 |
将成分(A)和(B)分别加热至70℃。然后将成分(B)加入成分(A)中,共同混合得到适于局部应用的乳化体形式的均质混合物。
Claims (11)
1.一种活性组分,其特征在于其中含有:作为活性成分硫辛酸,以及至少一种选自亚油酸、亚麻酸、油酸的聚烯醇脂肪酸。
2.权利要求1的活性组分,其中包含0.5-90%(重量)、优选5-50%(重量)的硫辛酸,剩余的百分比由至少一种选自亚油酸、亚麻酸和油酸的脂肪酸与溶剂、增溶剂和稀释剂构成或仅由该至少一种脂肪酸构成。
3.权利要求1和2的活性组分中的任一种,其中硫辛酸包括其还原成二氢硫辛酸的形式、右旋和左旋形式、外消旋混合物和相应的盐、酯和酰胺,聚烯醇脂肪酸包括相应的顺式和反式,盐,酯和酰胺。
4.一种药用、食用和美容用组合物,其中含有权利要求1的活性组分,其与至少一种选自以下的成分共用:视黄醇、视黄醛、生育酚、抗坏血酸、生物素、对氨基苯甲酸、芦丁胡、β-萝卜素、硫胺素、核黄素、吡哆辛、吡哆醛、烟碱酸、烟酸、烟酰胺、泛酸、泛醇、叶酸、卵磷脂、大豆磷脂例如如磷脂酰胆碱、磷脂酰乙醇胺、磷脂酸、溶血磷脂酰胆碱、PABA胡莫柳酯、樟脑甲硫酸苯甲烃铵、二苯酮-3、苯基苯并咪唑磺酸、丁基甲氧基苯甲酰甲烷、对苯二亚甲基二樟脑磺酸、亚苄基樟脑磺酸、氯双苯丙烯酸辛酯、甲氧基肉桂酸辛酯、聚丙烯酰氨基甲基亚苄基、PEG-25 PABA、水杨酸辛酯、二甲基PABA辛酯、对甲氧基肉桂酸异戊酯、二苯酮-4、3-亚苄基樟脑、4-甲基亚苄基樟脑、水杨酸异丙基苄酯、辛基-triazonesia、α-羟基酸和β-羟基酸,单羧酸和二羧酸,例如乙醇酸、乳酸(右旋和左旋形式,以及消旋混合物形式)、酒石酸(右旋和左旋形式,以及消旋混合物形式)、苹果酸(右旋和左旋形式,以及消旋混合物形式)、水杨酸、3-羟基苯甲酸、4-羟基苯甲酸、柠檬酸,这些成分可单用或共用,包括其相应的盐、酯和酰胺,以及相应的D-L-DL形式。
5.权利要求4的组合物,其中活性组分的用量为0.1-90%(重量),优选3-50%(重量),增效剂的用量为0.01-50%(重量)、优选0.05-15%(重量)。
6.权利要求4的组合物的药用用途,其可用于治疗与氧化作用有关的疾病的退化形式。
7.权利要求6的组合物的药用用途,其可用于治疗:特应性皮炎、脂溢性皮炎、钱币状皮炎、剥脱性皮炎、停滞性皮炎、神经性皮炎、痤疮、红斑痤疮、瘢痕性脱发、希波克拉底氏脱发、女性脱发、药物毒性脱发、aerate脱发、假性毛囊炎、牛皮癣、扁平红苔癣、鱼鳞癣、干皮病、角化病、褥疮、营养不良性溃疡、钝痛、血管瘤、haemangioma、毛细管扩张肉芽瘤、脂溢性角化病、纤维组织细胞瘤、硬斑病,治疗肥大性瘢痕、烧伤瘢痕、毛细管扩张,改善循环和微循环、瘀血、血管淤滞、红斑狼疮、硬皮病、伤口结瘢、瘢痕疙瘩、组织不定形成分的变性形式、静脉淤滞、动脉淤滞、风湿性关节炎、骨关节炎、关节病、硬皮病、氧自由基型中毒等。
8.权利要求4的组合物的美容用途,其可用于护理和预防皮肤过度色素沉着。
9.权利要求7的组合物的美容用途,其可用于滋润、抗老化、抗皱、爽肤、抗蜂窝组织炎、秃发的美容护理、面部发红的美容护理、治疗毛细管扩张、couperose、化学性脱皮,以及用于营养作用。
10.权利要求4的组合物的食用用途,其可用于刺激身体代谢从而具有减肥作用。
11.权利要求4的组合物的食用用途,其作用是抑制自由基引发的氧化。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2001TO000272A ITTO20010272A1 (it) | 2001-03-23 | 2001-03-23 | Motore a combustione interna con valvole ad azionamento variabile e punteria idraulica ausiliaria. |
IT000027A/2001 | 2001-03-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1376461A true CN1376461A (zh) | 2002-10-30 |
Family
ID=11458720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN02107839A Pending CN1376461A (zh) | 2001-03-23 | 2002-03-22 | 基于硫辛酸和聚烯醇脂肪酸的活性组分 |
Country Status (8)
Country | Link |
---|---|
US (1) | US6553950B2 (zh) |
EP (1) | EP1245799B1 (zh) |
JP (1) | JP4046527B2 (zh) |
CN (1) | CN1376461A (zh) |
AT (1) | ATE270383T1 (zh) |
DE (1) | DE60200669T2 (zh) |
ES (1) | ES2219596T3 (zh) |
IT (1) | ITTO20010272A1 (zh) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6752121B2 (en) * | 2001-05-18 | 2004-06-22 | General Motors Corporation | Cylinder deactivation system timing control synchronization |
ITTO20011187A1 (it) | 2001-12-18 | 2003-06-18 | C R F Societa Con Sortile Per | ,,motore pluricilindrico a benzina con azionamento variabile delle valvole,, |
DE10205888B4 (de) * | 2002-02-13 | 2009-01-15 | Delphi Technologies, Inc., Troy | Hydraulische Ventilbetätigungsvorrichtung |
DE10224039A1 (de) * | 2002-05-31 | 2003-12-11 | Ina Schaeffler Kg | Hydraulisch betätigter, variabler Ventiltrieb einer Brennkraftmaschine |
US7080614B2 (en) | 2002-05-31 | 2006-07-25 | Ina-Schaeffler Kg | Hydraulically actuated, variable valve drive of an internal combustion engine |
US6718846B1 (en) * | 2003-04-24 | 2004-04-13 | Caterpillar Inc. | Apparatus for aligning a bearing member with an actuator |
ES2279329T3 (es) | 2004-01-16 | 2007-08-16 | C.R.F. Societa' Consortile Per Azioni | Motor de combustion interna con un unico arbol de levas que controla las valvulas de escape de forma mecanica, y las valvulas de admision por medio de un dispositivo hidraulico controlado electronicamente. |
EP1635046B1 (en) * | 2004-09-14 | 2007-04-25 | C.R.F. Società Consortile per Azioni | Internal combustion engine having valves with variable actuation and hydraulic actuating units which control the valves by means of rocker arms |
DE102007053981A1 (de) * | 2007-11-13 | 2009-05-14 | Schaeffler Kg | Baueinheit eines Ventiltriebs einer Brennkraftmaschine |
DE602008001371D1 (de) | 2008-04-10 | 2010-07-08 | Fiat Ricerche | Turbokraftstoffmotor mit variabler Steuerung der Aufnahmeventile |
ATE499511T1 (de) | 2008-11-07 | 2011-03-15 | Fiat Ricerche | Dieselmotor mit variabler einlassventilbetätigung und einer internen abgasrückführung |
ATE520866T1 (de) | 2008-11-07 | 2011-09-15 | Fiat Ricerche | Dieselmotor mit nocken zum betätigen von einlassventilen, welche einen hauptnocken und einen hilfsnocken, die miteinander verbunden sind,aufweisen |
US8251033B2 (en) * | 2008-11-24 | 2012-08-28 | General Electric Company | System and method for varying a duration of a closing phase of an intake valve of an engine |
EP2204566B1 (en) | 2008-12-29 | 2011-06-29 | Fiat Group Automobiles S.p.A. | Adaptive control system of the air-fuel ratio of an internal combustione engine with a variable valve timing system |
DE102009054054A1 (de) * | 2009-11-20 | 2011-05-26 | Schaeffler Technologies Gmbh & Co. Kg | Montageanordnung und Verfahren zur Montage eines Druckspeichers für Brennkraftmaschinen |
EP2397674B1 (en) | 2010-06-18 | 2012-10-24 | C.R.F. Società Consortile per Azioni | Internal combustion engine with cylinders that can be de-activated, with exhaust gas recirculation by variable control of the intake valves, and method for controlling an internal combustion engine |
DE102011004403A1 (de) | 2011-02-18 | 2012-08-23 | Schaeffler Technologies Gmbh & Co. Kg | Hydraulischer Ventiltrieb einer Brennkraftmaschine |
US8701607B2 (en) | 2011-08-25 | 2014-04-22 | Chrysler Group Llc | System and method for engine valve lift strategy |
DK177481B1 (en) * | 2012-03-27 | 2013-07-08 | Man Diesel & Turbo Deutschland | Gas exchange valve for internal combustion engine |
EP2653703B1 (en) | 2012-04-19 | 2014-04-30 | C.R.F. Società Consortile per Azioni | Internal combustion engine with cylinders which can be deactivated, in which the deactivated cylinders are used as pumps for recirculating exhaust gases into the active cylinders, and method for controlling this engine |
US9091184B2 (en) | 2013-03-31 | 2015-07-28 | Jacobs Vehicle Systems, Inc. | Controlling motion of a moveable part |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4796573A (en) * | 1987-10-02 | 1989-01-10 | Allied-Signal Inc. | Hydraulic engine valve lifter assembly |
US4887562A (en) * | 1988-09-28 | 1989-12-19 | Siemens-Bendix Automotive Electronics L.P. | Modular, self-contained hydraulic valve timing systems for internal combustion engines |
US5127375A (en) * | 1991-04-04 | 1992-07-07 | Ford Motor Company | Hydraulic valve control system for internal combustion engines |
IT1285853B1 (it) * | 1996-04-24 | 1998-06-24 | Fiat Ricerche | Motore a combustione interna con valvole ad azionamento variabile. |
JP2001518587A (ja) * | 1997-08-28 | 2001-10-16 | ディーゼル エンジン リターダーズ,インコーポレイテッド | 油圧弁アクチュエータ |
WO1999027242A2 (en) * | 1997-11-21 | 1999-06-03 | Diesel Engine Retarders, Inc. | Device to limit valve seating velocities in limited lost motion tappets |
IT1302071B1 (it) * | 1998-02-26 | 2000-07-20 | Fiat Ricerche | Motore a combustione interna con valvole ad azionamento variabile. |
GB2348245B (en) * | 1999-03-25 | 2002-10-23 | Ricardo Inc | Valvegear for engines of reciprocating piston type |
IT1307361B1 (it) * | 1999-10-06 | 2001-11-06 | Fiat Ricerche | Perfezionamenti ai motori a combustione interna con valvole adazionamento variabile. |
-
2001
- 2001-03-23 IT IT2001TO000272A patent/ITTO20010272A1/it unknown
-
2002
- 2002-03-13 ES ES02005747T patent/ES2219596T3/es not_active Expired - Lifetime
- 2002-03-13 DE DE60200669T patent/DE60200669T2/de not_active Expired - Lifetime
- 2002-03-13 AT AT02005747T patent/ATE270383T1/de active
- 2002-03-13 EP EP02005747A patent/EP1245799B1/en not_active Expired - Lifetime
- 2002-03-22 US US10/102,753 patent/US6553950B2/en not_active Expired - Lifetime
- 2002-03-22 CN CN02107839A patent/CN1376461A/zh active Pending
- 2002-03-25 JP JP2002083332A patent/JP4046527B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1245799B1 (en) | 2004-06-30 |
JP2002322904A (ja) | 2002-11-08 |
ES2219596T3 (es) | 2004-12-01 |
JP4046527B2 (ja) | 2008-02-13 |
US6553950B2 (en) | 2003-04-29 |
ITTO20010272A1 (it) | 2002-09-23 |
EP1245799A3 (en) | 2003-07-02 |
ITTO20010272A0 (it) | 2001-03-23 |
EP1245799A2 (en) | 2002-10-02 |
DE60200669D1 (de) | 2004-08-05 |
ATE270383T1 (de) | 2004-07-15 |
DE60200669T2 (de) | 2005-08-25 |
US20020134330A1 (en) | 2002-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1376461A (zh) | 基于硫辛酸和聚烯醇脂肪酸的活性组分 | |
EP0831767B1 (en) | Alpha hydroxyacid esters for skin aging | |
DE69023574T2 (de) | Amphotere Zusammensetzungen und Polymerformen von alpha-Hydroxy-Säuren, und ihre therapeutische Anwendung. | |
CN110787093B (zh) | 一种双剂型精华及其制备方法 | |
US6358539B1 (en) | Pharmaceutical compositions for reducing the appearance of cellulite | |
CN110785161B (zh) | 用于改善皮肤外观的组合物和方法 | |
KR101239344B1 (ko) | 글리세릴 및 글리콜산 화합물 | |
US20050129787A1 (en) | Pharmaceutical compositions and methods for managing connective tissue ailments | |
CN1376048A (zh) | 皮肤护理组合物 | |
CN108430449A (zh) | 处理皮肤状况的方法以及用于其的组合物 | |
ITBS20010027A1 (it) | Principio attivo a base di acido lipoico ed acidi grassi polienolici | |
CN101203145B (zh) | 使用甘油酯治疗角质干燥 | |
Thueson et al. | The roles of pH and concentration in lactic acid-induced stimulation of epidermal turnover | |
CN111035572B (zh) | 一种具有美白功效纳米结构脂质体及其制备方法和化妆品 | |
CN115778857B (zh) | 一种具有滋养抗衰老效果的复合植物油脂纳米乳液、其制备方法及应用 | |
CN111991257A (zh) | 一种防晒增效组合物及其在制备化妆品中的应用 | |
CN108836896B (zh) | 一种稳定的用于护肤品和化妆品的鱼油乳 | |
AU2005243198A1 (en) | Topical regulation of triglyceride metabolism | |
CN1771028A (zh) | 用于治疗或预防刺激、发炎和皮肤红斑的含二甲砜的化妆品和/或药物组合物 | |
JP2005104894A (ja) | 油性化粧料 | |
EP2671566A1 (en) | External skin preparation | |
KR102099251B1 (ko) | 불등풀가사리를 포함하는 해조혼합 발효물 및 이를 유효성분으로 함유하는 화장료 조성물 | |
CN1096669A (zh) | 丝肽貂油润肤膏 | |
JP2000290165A (ja) | 皮膚老化抑制剤およびその用途 | |
FR2720938A1 (fr) | Composition dermato-cosmétologique et son utilisation. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |